Key clinical point: Anti-CD5 chimeric antigen receptor (CAR) T cells can produce complete responses (CRs) in patients with relapsed/refractory T-cell malignancies.
Major finding: Three patients achieved a CR after CAR T-cell therapy, and one patient achieved a mixed response that deepened to a CR after transplant.
Study details: A phase 1 trial of 11 treated patients.
Disclosures: The trial is sponsored by Baylor College of Medicine. Dr. Hill reported having no conflicts of interest.
Hill L et al. ASH 2019, Abstract 199.